|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:ITX-Saemaeul
|
|
gptkbp:activities
|
inhibitor of specific pathways
|
|
gptkbp:analysis
|
in progress
|
|
gptkbp:analyzes
|
gptkb:Dr._Smith
gptkb:Dr._Johnson
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:USA
ongoing
overall survival
progression-free survival
|
|
gptkbp:collaborations
|
gptkb:ABC_Pharma
|
|
gptkbp:developed_by
|
gptkb:ITX_Therapeutics
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:dosage_form
|
titrated
|
|
gptkbp:frequency
|
once daily
|
|
gptkbp:future_plans
|
expand trials
file for approval
seek partnerships
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ITX-1
|
|
gptkbp:indication
|
solid tumors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:investment
|
high
|
|
gptkbp:is_effective_against
|
promising
|
|
gptkbp:is_tested_for
|
Phase 1
specific genetic mutations
|
|
gptkbp:manager
|
oral
|
|
gptkbp:pharmacokinetics
|
studied
analyzed
|
|
gptkbp:population
|
diverse
|
|
gptkbp:products
|
filed
|
|
gptkbp:publishes
|
published
submitted
in press
|
|
gptkbp:receives_funding_from
|
private investment
government grant
|
|
gptkbp:regulatory_compliance
|
not yet approved
|
|
gptkbp:research
|
completed
|
|
gptkbp:research_areas
|
gptkb:University_of_XYZ
|
|
gptkbp:research_focus
|
oncology
|
|
gptkbp:safety_features
|
ongoing
acceptable
|
|
gptkbp:side_effect
|
fatigue
nausea
monitored
diarrhea
|
|
gptkbp:social_structure
|
C20 H25 N3 O3 S
|
|
gptkbp:status
|
gptkb:legal_case
|
|
gptkbp:student_enrollment
|
ongoing
|
|
gptkbp:target_audience
|
adults
|
|
gptkbp:targets
|
gptkb:healthcare_organization
|
|
gptkbp:treatment
|
under investigation
|
|
gptkbp:type
|
gptkb:Cloud_Computing_Service
|
|
gptkbp:weight
|
375.55 g/mol
|
|
gptkbp:year_created
|
gptkb:2020
|